Prostate Cancer
Conditions
Interventions
experimental group:IRE + NHT
control group:NHT
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
Male
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Age 40-85 years. Histologically or cytologically confirmed prostate cancer. Whole-body bone scan (ECT), whole-body MRI, or PET-CT/MRI (FDG/PSMA) confirming the presence of metastatic lesions (bone metastasis or lymph node metastasis). Expected survival >12 months. ECOG performance status score =3. No prior radical surgery or radiation therapy for the primary lesion of prostate cancer. Tumor diameter of the primary prostate tumor =4cm, and no more than 3 lesions. Signed informed consent.
Exclusion criteria
Exclusion criteria: Experienced a seizure within 1 month before enrollment. Histologically or cytologically confirmed prostate neuroendocrine carcinoma. Whole-body MRI or PET-CT/MRI (FDG/PSMA) confirming the presence of visceral metastatic lesions. Presence of second-degree or higher atrioventricular block or a history of cardiac pacemaker implantation. Implantation of electronic devices or metal parts near the ablation area. Absence of anus after rectal or anal surgery or congenital absence of the anus. Contraindications to chemotherapy or hormonal therapy. Deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| DCR;PSA responce rate;BCR;PSA-PFS;rPFS;OS;pain score;function score;IPSS;Qmax;complication rate; | — |
Countries
China
Contacts
Public ContactLiu Ming
Beijing Hospital
Outcome results
None listed